Kobe, Japan

Tomoyuki Nishizaki



Average Co-Inventor Count = 1.6

ph-index = 2

Forward Citations = 13(Granted Patents)


Location History:

  • Hyogo, JP (2017)
  • Kobe, JP (2008 - 2019)

Company Filing History:


Years Active: 2008-2019

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: Tomoyuki Nishizaki: Innovator in Diabetes and Anti-Aging Therapies

Introduction

Tomoyuki Nishizaki is a prominent inventor based in Kobe, Japan. He has made significant contributions to the fields of diabetes treatment and anti-aging therapies. With a total of 10 patents, his work focuses on innovative solutions that address critical health issues.

Latest Patents

One of his latest patents is a GLUT4 endocytosis inhibitor. This invention provides a therapeutic drug for diabetes that contains 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine (DOPE) as an active ingredient. It specifically aims to suppress GLUT4 endocytosis by inhibiting the activation of PKCα and similar pathways. Another notable patent is an elastin synthesis and regeneration promoting agent. This agent, 8-[2-(2-Pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid (DCP-LA), promotes the synthesis and regeneration of elastin, making it useful for preventing and improving wrinkles, as well as serving as an anti-aging drug.

Career Highlights

Throughout his career, Tomoyuki Nishizaki has worked with various organizations, including the Nishizaki Bioinformation Research Institute and Tox K.K. His innovative research has positioned him as a key figure in the development of therapeutic solutions for age-related conditions and metabolic disorders.

Collaborations

Some of his notable coworkers include Akito Tanaka and Takashi Nakano. Their collaborative efforts have contributed to the advancement of research in their respective fields.

Conclusion

Tomoyuki Nishizaki's contributions to medical science through his patents and research are noteworthy. His work continues to impact the fields of diabetes treatment and anti-aging therapies significantly.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…